

## Review

**Clinical review: Patency of the circuit in continuous renal replacement therapy**Michael Joannidis<sup>1</sup> and Heleen M Oudemans-van Straaten<sup>2</sup><sup>1</sup>Medical Intensive Care Unit, Division of General Internal Medicine, Department of Internal Medicine, Medical University Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria<sup>2</sup>Department of Intensive Care Medicine, Onze Lieve Vrouwe Gasthuis, Oosterpark 9, 1091 AC Amsterdam, The NetherlandsCorresponding author: Heleen M Oudemans-van Straaten, [h.m.oudemans-vanstraaten@olvg.nl](mailto:h.m.oudemans-vanstraaten@olvg.nl)

Published: 12 July 2007

This article is online at <http://ccforum.com/content/11/4/218>

© 2007 BioMed Central Ltd

*Critical Care* 2007, **11**:218 (doi:10.1186/cc5937)**Abstract**

Premature circuit clotting is a major problem in daily practice of continuous renal replacement therapy (CRRT), increasing blood loss, workload, and costs. Early clotting is related to bioincompatibility, critical illness, vascular access, CRRT circuit, and modality. This review discusses non-anticoagulant and anticoagulant measures to prevent circuit failure. These measures include optimization of the catheter (inner diameter, pattern of flow, and position), the settings of CRRT (partial predilution and individualized control of filtration fraction), and the training of nurses. In addition, anticoagulation is generally required. Systemic anticoagulation interferes with plasmatic coagulation, platelet activation, or both and should be kept at a low dose to mitigate bleeding complications. Regional anticoagulation with citrate emerges as the most promising method.

**Introduction**

During continuous renal replacement therapy (CRRT), blood is conducted through an extracorporeal circuit, activating coagulation by a complex interplay of patient and circuit. Critically ill patients may develop a procoagulant state due to early sepsis, hyperviscosity syndromes, or antiphospholipid antibodies. In early sepsis, activation of the coagulation system is triggered by proinflammatory cytokines that enhance the expression of tissue factor on activated mononuclear and endothelial cells and simultaneously downregulate natural anticoagulants, thus initiating thrombin generation, subsequent activation of platelets, and inhibition of fibrinolysis [1].

Initiation of clotting in the extracorporeal circuit traditionally has been attributed to contact activation of the intrinsic coagulation system (Figure 1). However, the bioincompatibility reaction is more complex and is incompletely understood. Activation of tissue factor, leucocytes, and platelets play an additional role [2]. However, thrombin activation has been

observed even without detectable systemic activation of these systems [3,4]. Some of these processes may occur locally at the membrane. Other reasons for premature clotting related to the CRRT technique are repeated stasis of blood flow [5], hemoconcentration, turbulent blood flow, and blood-air contact in air-detection chambers [6]. Circuit clotting has further been observed in association with a high platelet count and platelet transfusion [7,8]. Premature clotting reduces circuit life and efficacy of treatment and increases blood loss, workload, and costs of treatment. Therefore, improving circuit life is clinically relevant.

The interpretation of studies evaluating circuit life in CRRT, however, is hampered by the complexity and interplay of the factors mentioned. Furthermore, circuits are disconnected because of imminent clotting, protein adsorption to the membrane causing high transmembrane pressures (clogging), or logistic reasons such as transport or surgery. In addition, some units change filters routinely after 24 to 72 hours. Despite a lack of proof supported by large randomized trials, several measures seem sensible for prolonging patency of the CRRT circuit.


One major intervention to influence circuit life is anticoagulation. Given a recent review on anticoagulation strategies in CRRT [9], this overview also incorporates the role of non-anticoagulant measures for circuit survival.

**Non-anticoagulant measures to improve circuit life****1. Reducing stasis of flow***Vascular access*

Vascular access is a major determinant of circuit survival. Both high arterial and venous pressures are detrimental. Access

aPTT = activated partial thromboplastin time; AT = antithrombin; CRRT = continuous renal replacement therapy; CVVH = continuous venovenous hemofiltration; CVVHD = continuous venovenous hemodialysis; CVVHDF = continuous venovenous hemodiafiltration; HIT = heparin-induced thrombocytopenia; Ht = hematocrit; iCa = ionized calcium; LMWH = low molecular weight heparin; PF-4 = platelet factor-4; PG = prostaglandin; QB = blood flow; QF = ultrafiltrate flow; rhAPC = recombinant human activated protein C; UFH = unfractionated heparin.

Figure 1



Mechanism of contact activation by hemofilter membranes. ADP, adenosine diphosphate; C, complement factor; GP, glycoprotein; HMWK, high molecular weight kininogens; PAF, platelet activating factor released by polymorphonuclear cells; plt., platelets; RBC, red blood cells; TF, tissue factor expressed by adhering monocytes; TXA, thromboxane  $A_2$ .

failure causes blood flow reductions, which are associated with early circuit clotting [5]. *In vitro* studies have found that high venous pressures in the circuit reduce circuit life [10]. Randomized studies in critically ill patients on CRRT which evaluate the effect of catheter site or design on circuit flow and survival are not available. Most information comes from observational and *in vitro* studies in chronic hemodialysis patients, who need their catheters intermittently and for a much longer time (reviewed in [11]). Some general principles are summarized in Figure 2 and are discussed below.

According to Poiseuille's law, flow through a catheter is related to the fourth power of radius and inversely related to length, indicating that a thick (13 to 14 French) and short catheter is preferable. However, a more central position of the tip improves flow, dictating sufficient length. In chronic dialysis patients, best flows are obtained with the tip in the right atrium [12,13]. With the femoral route, tip position should be positioned in the inferior caval vein. Because the inner diameter counts, the material is crucial. In general, silicone catheters have thicker walls than polyurethane catheters. Another issue is the presence of side or end holes. Flow through end holes is laminar, which is optimal, whereas flow through side holes is turbulent and even locally stagnant, contributing to early clotting. Suctioning of side holes against the vessel wall may impair flow, which is minimized with side holes over the (near) total circumference and absent with end holes. Another important determinant of catheter flow is the patient's circulation. For example, catheter dysfunction was found to be associated with low central venous pressure [12].

Furthermore, kinking of the catheter may impair catheter flow. Subclavian access has an enhanced risk of kinking and of

stenosis with longer catheter stay [14-16]. The right jugular route is the straightest route. Furthermore, high abdominal pressures or high or very negative thoracic pressures, occupancy by other catheters, patency or accessibility of veins, anatomy, posture, and mobility of the patient determine choice of the site. Ultrasound-guided catheter placement significantly reduces complications [17]. An important issue is locking of the CRRT catheter when not in use by controlled saline infusion or by blocking with heparin or citrate solutions to prevent fibrin adhesion, which slowly reduces lumen diameter [18,19].

#### Training of nurses






Slow reaction to pump alarms contributes to stasis of flow and early filter clotting. Training includes the recognition and early correction of a kinked catheter and the adequate rinsing of the filter before use since blood-air contact activates coagulation [20,21]. Intermittent saline flushes have no proven efficacy [22]. Filling of the air detection chamber to at least two thirds minimizes blood-air contact.

## 2. Optimizing continuous renal replacement therapy settings

### Filtration versus dialysis

For several reasons, continuous venovenous hemofiltration (CVVH) appears to be associated with shorter circuit life than continuous venovenous hemodialysis (CVVHD) [23]. First, for the same CRRT dose, hemofiltration requires higher blood flows. Higher blood flows give more flow limitation and more frequent stasis of blood flow. Second, hemofiltration is associated with hemoconcentration, occurring as a consequence of ultrafiltration. Within the filter, hematocrit (Ht), platelet count, and coagulation factors increase the likelihood of coagulation. Continuous venovenous hemodiafiltration

**Figure 2**

	Qualification	Pro	Con
<b>Characteristic of catheter</b>			
Diameter	Higher	Q increases	Vascular occlusion
Length	Longer	Q increases if the tip is in RA/ICV	Q is inversely related to length
	Shorter	Q increases	Q decreases if the tip is in jugular vein or iliac vein, especially with hypovolemia
Material	(Modified) polyurethane	Thin wall: higher inner diameter leads to increases in Q	Rather stiff: more kinking
	Silicone	High biocompatibility and less thrombogenic pliancy lead to less kinking	Thicker wall: smaller inner diameter leads to an increase in Q
	Heparin coating	Thrombogenicity decreases	Short duration of effect
<b>Design</b>			
Co-axial		Side holes over entire circumference: less suction to vessel wall Tapering tip: easy insertion	Side holes: turbulent and stagnant flow leads to clotting
Double D		Tapering tip: easy insertion	One-sided side holes: suctioning against vessel wall and turbulent and stagnant flow lead to clotting
Cycle C		Tapering tip: easy insertion Side holes over almost entire circumference	Side holes (see above)
Split tip		No side holes: laminar flow, less recirculation?	No tapering tip: pre-dilatation is important
Shotgun		No side holes: laminar flow, less clotting?	No tapering tip: pre-dilatation is important
Coating	Heparin	Less clotting	Short-term effect
Choice of central vein	Jugular	Easy access Straight route Q increases if position is in RA	Q decreases with high or negative intra-thoracic pressures Saliva contamination
	Femoral	Easy access Rather straight route Q increases if position is in ICV	Fecal contamination Q decreases due to longer length
	Subclavian	Clean site Comfortable site	Kinking Risk of late vascular stenosis Q decreases with high intra-thoracic P
Position of patient	Q is linearly related to $\Delta P$ over catheter	(Near) horizontal position	Q decreases with sitting, highly negative thoracic P, high thoracic, or intra-abdominal P
Catheter 'lock'	Intravenous saline pump	Safe	Infusion pump
	Heparin	Effective	Minor systemic effect
	Citrate	Effective Fewer infections Less biofilm	Risk of hypotension if not suctioned before re-use

Features of vascular access contributing to extracorporeal blood flow. ICV, inferior caval vein; P, pressure; Q, blood flow; RA, right atrium.

(CVVHDF) combines the possible advantages of hemofiltration (higher middle molecular clearance) with less hemoconcentration. Higher solute clearances can be attained at relatively lower blood flows and may thus increase circuit survival. However, a prospective survey in children on 442 CRRT circuits (heparin and citrate) could not find a

correlation between circuit survival and CRRT mode (CVVH, CVVHD, or CVVHDF) [24].

*Filtration fraction or postfilter hematocrit*

To minimize the procoagulant effects of hemoconcentration, it is recommended to keep the filtration fraction (the ratio of

ultrafiltrate flow [QF] to blood flow [QB]) as low as possible; a value below 25% is generally recommended in postdilution mode. It may be more rational to adjust the filtration fraction to the patient's Ht because blood viscosity in the filter is the limiting factor. Although many factors contribute to blood viscosity, Ht is the main determinant and is available at bedside. A Ht in the filter ( $Ht_{\text{filter}}$ ) of 0.40 may be acceptable.  $Ht_{\text{filter}}$  and the minimal QB required for the prescribed QF can be calculated at bedside.

$$Ht_{\text{filter}} = QB \times Ht_{\text{patient}} / (QB - QF),$$

$$QB = QF \times (Ht_{\text{filter}} / (Ht_{\text{filter}} - Ht_{\text{patient}})).$$

Another option for reducing the filtration fraction is to administer (part of) the replacement fluid before the filter.

#### *Predilution versus postdilution*

In predilution CRRT, substitution fluids are administered before the filter, thus diluting the blood in the filter, decreasing hemoconcentration, and improving rheological conditions. One small randomized cross-over study ( $n = 15$ ) and one study comparing 33 patients on predilution CVVH to 15 historical postdilution controls found longer circuit survival with predilution [25,26] at the cost of a diminished clearance [26]. However, compared to the historical controls, mean daily serum creatinine changes were not significantly different [25]. Reduced filter downtime may compensate for the lower predilution clearance. Predilution particularly reduces middle molecular clearance [27], the clinical consequences of which are still unclear.

#### *Clogging*

Clogging is due to the deposition of proteins and red cells on the membrane and leads to decreased membrane permeability. Clogging is detected by declining sieving coefficients of larger molecules and increasing transmembrane pressures. Clogging enhances the blockage of hollow fibers as well. The process is still incompletely understood, but interplay between the protein constitution of plasma, rheological characteristics of blood, capillary and transmembrane flow, membrane characteristics, and possibly the use of different resuscitation fluids influence this process [10,27]. It has been suggested that with predilution, membrane performance is better maintained by reducing protein adsorption. On the other hand, others have shown more protein adsorption with predilution [28]. This may be explained by the higher ultrafiltration rate, opening more channels and thus increasing the actual surface and the amount of protein adsorbed. Future developments to reduce protein adsorption include hydrophilic modification of polyethersulfone [29].

#### *Membranes*

Biocompatibility is significantly influenced by membrane characteristics. Main determinants are electronegativity of membrane surface and its ability to bind plasma proteins, as

well as complement activation, adhesion of platelets, and sludging of erythrocytes [30] (Figure 1). Few studies have evaluated the influence of membrane material on filter run times. Membranes with high absorptive capacity generally have a higher tendency to clot. In a non-randomized controlled study, polyamide exhibited later clotting than acrylonitrile (AN69) [31]. Modification of existing membranes to increase heparin binding (AN69ST) reduced clotting in intermittent hemodialysis [32]. Newer membranes with various polyethersulfone coatings that reduce activation of coagulation are being developed [33]. Up to now, large randomized controlled trials evaluating the influence of the type of membrane on circuit life during CRRT have been missing.

#### *Filter size*

Filter size may play a role and larger surfaces may be of relevance for filter survival and solute clearance when CVVHD is applied. A comparison of two polysulphone hemofilters with different hollow fiber lengths showed transmembrane pressure and increased survival time being lower with the longer filter [34].

## **Anticoagulation**

Anticoagulation of the extracorporeal circuit is generally required. However, systemic anticoagulation may cause bleeding [31]. The risk of bleeding in critically ill patients is high because of frequent disruption of the vascular wall and coagulopathy. Therefore, clinicians search for alternatives such as CRRT without anticoagulation [35-38], increasing natural anticoagulants, minimal systemic anticoagulation, or regional anticoagulation.

#### *1. Increasing natural anticoagulants*

Heparin acts by a 1,000-fold potentiation of antithrombin (AT) to inhibit factors Xa and IIa (thrombin). Low levels of AT decrease heparin activity and are associated with premature clotting of the circuit [3,39,40]. In a non-randomized study in patients on CRRT, AT deficiency (less than 60%) was associated with early filter clotting, whereas supplementation increased circuit life [41]. In a recent retrospective case control study in patients with septic shock undergoing CRRT with heparin, supplementation of AT to keep plasma concentration above 70% increased circuit survival time [42].

Recombinant human activated protein C (rhAPC), used in severe sepsis, inhibits the formation of thrombin by degrading coagulation factors Va and VIIIa. Furthermore, it might decrease the synthesis and expression of tissue factor and enhance fibrinolysis [43]. During administration of rhAPC, additional anticoagulation for CRRT is probably not required [44].

#### *2. Minimal systemic anticoagulation*

Systemic anticoagulation inhibits plasmatic coagulation, platelet function, or both. Low-dose anticoagulation is usually sufficient to keep the filter patent and mitigates the increased

risk of bleeding associated with full anticoagulation. Effects in the circuit are highest with local administration.

### **Interference with plasmatic coagulation**

#### *Unfractionated heparin*

Unfractionated heparin (UFH) is the predominant anticoagulant. Its major advantages are the low costs, ease of administration, simple monitoring, and reversibility with protamine [9,45]. The half-life of UFH is approximately 90 minutes, increasing to up to 3 hours in renal insufficiency due to accumulation of the smaller fragments. Monitoring with activated partial thromboplastin time (aPTT) is still the best option. Retrospective analyses indicate increased bleeding if systemic aPTT is longer than 45 seconds [31]. At this low level of anticoagulation, activated clotting time is relatively insensitive for monitoring [46]. However, aPTT appears to be an unreliable predictor of bleeding [9,47]. Given these limitations, a possible scheme for UFH consists of a bolus of 30 IU/kg followed by an initial rate of 5 to 10 IU/kg per hour in patients with normal coagulation. However, the level of anticoagulation should be individualized. Apart from bleeding, major side effects of UFH include development of heparin-induced thrombocytopenia (HIT), hypoaldosteronism, effects on serum lipids, and AT dependency [47].

#### *Low molecular weight heparins*

Low molecular weight heparins (LMWHs) exhibit several advantages, including lower incidence of HIT [48], lower AT affinity, less platelet and polymorphonuclear cell activation, less inactivation by platelet factor-4 (PF-4), higher and more constant bioavailability, and lack of metabolic side effects [47,49,50]. However, data on the use of LMWH in CRRT are limited [7,51-53]. Dalteparin, nadroparin, and enoxaparin have been investigated. Their mean molecular weight is between 4.5 and 6 kDa, and their mean half-life ranges from 2.5 to 6 hours and is probably even longer in renal insufficiency. However, there are indications that LMWHs are eliminated by CRRT [54]. Although some studies use LMWH in a fixed dose [7,52], continuous intravenous application of LMWH, aiming at systemic anti-FX levels of 0.25 to 0.35 U/ml, may be the safest option [53]. However, anti-Xa may not be a reliable predictor of bleeding [55] and anti-Xa determinations are not generally available.

#### *Heparin-induced thrombocytopenia*

HIT is caused by a heparin-induced antibody that binds to the heparin-PF-4 complex on the platelet surface. This may or may not lead to platelet activation and consumption, thrombocytopenia, and both arterial and venous thrombosis. Depending on the dose and type of heparin, the population, and the criteria used, 1% to 5% of treated patients develop HIT [56]. Platelet count typically rapidly decreases by more than 50% after approximately 1 week or earlier after previous use of heparin. Diagnosis depends on a combination of clinical and laboratory results [57]. A reliable diagnosis is complicated by the fact that the incidence of a false-positive

enzyme-linked immunosorbent assay test is high [58]. Unfortunately, the more precise carbon 14-serotonin release assay is not routinely available. Awaiting final diagnosis, all kinds of heparins should be discontinued and an alternative anticoagulant started.

There are no randomized controlled trials showing which anticoagulant is best for HIT. The choice depends on local availability and monitoring experience. If citrate is used for anticoagulation of the circuit, separate thromboprophylaxis must be applied. Inhibition of thrombin generation can be obtained via direct inhibition of FIIa (r-hirudin, argatroban, or dermatan sulphate), FXa (danaparoid or fondaparinux), or both (nafamostat). Inhibition of platelet activation can be obtained by the use of prostaglandins (PGs) (summarized in [9,59]). The use of r-hirudin is discouraged because of severe adverse events, extremely long half-life (170 to 360 hours), and the requirement of ecarin clotting time for monitoring [60]. Given the long half-life of fondaparinux and danaparoid (more than 24 hours), monitoring of anti-Xa is mandatory. The clinical relevance of cross-reactivity of danaparoid with HIT antibodies is not known [61]. Argatroban might be preferred because it is cleared by the liver and monitoring with aPTT seems feasible [62-65]. The half-life is approximately 35 minutes in chronic dialysis, but longer in the critically ill. Up to now, clinical data in CRRT and availability of the drug have been limited.

### **Interference with platelet activation**

Inhibition of platelet activation by PGs appears to be justified because the extracorporeal generation of thrombin and the use of heparin cause platelet activation. Both PGE<sub>1</sub> and PGI<sub>2</sub> have been investigated in CRRT, alone or in combination with heparins. The exclusive use of PGs in CVVH (1.5 liters per hour in predilution) provided a rather short circuit survival (median, 15 hours) [66]. Nevertheless, PGs may be a safe initial alternative when HIT is suspected. They can even be used in patients with hepatic and renal failure [67]. Significant improvement of circuit survival, however, could be achieved only when PGs were combined with low-dose UFH or LMWH [68-70]. PGs are administered in doses of 2 to 5 ng/kg per minute. Major drawbacks for routine use are their high costs and hypotension due to vasodilatation, but the half-life of the vasodilatory effect is as short as 2 minutes.

### **Regional anticoagulation with citrate**

#### *Anticoagulation*

Regional anticoagulation can be achieved by the prefilter infusion of citrate. Citrate chelates calcium, decreasing ionized calcium (iCa) in the extracorporeal circuit. For optimal anticoagulation, citrate flow is adjusted to blood flow, targeting at a concentration of 3 to 5 mmol/l in the filter [71]. Postfilter iCa can be used for fine tuning of the level of anticoagulation, aiming at a concentration of iCa of less than 0.35 mmol/l (Table 1). However, others prefer a fixed citrate dose and do not monitor iCa in the circuit, thereby simplifying the procedure (summarized in [9]). Citrate is partially

**Table 1**

**Different options for adjustment of anticoagulation with citrate**


Anticoagulant target	Pro	Con
Calculated [citrate] in filter 3-5 mmol/l	Fixed ratio of citrate flow and blood flow No extra monitoring Fixed buffer supply to patient	Anticoagulation may not be optimal
[iCa <sup>++</sup> ] postfilter 0.25-0.35 mmol/l	Optimal anticoagulation	Monitoring of postfilter iCa <sup>++</sup> Adjustment of citrate flow gives varying buffer supply to patient

iCa<sup>++</sup>, ionized calcium.

removed by convection or diffusion and partially enters the systemic circulation, where iCa rises again due to the dilution of extracorporeal blood, the liberation of chelated calcium when citrate is metabolized, and the replacement of calcium. As a result, systemic effects on coagulation do not occur.

*Buffer*

Apart from being an anticoagulant, citrate is a buffer substrate. The generation of buffer is related to the conversion of sodium citrate to citric acid:



Citric acid enters the mitochondria and is metabolized in the Krebs cycle, mainly in the liver but also in skeletal muscle and the renal cortex, leaving sodium bicarbonate.

*Removal and accumulation of citrate*

Citrate removal by CRRT mainly depends on CRRT dose and not on modality. Citrate clearance approximates urea clearance. The sieving coefficient is between 0.87 and 1.0 and is not different between CVVH and CVVHD [72,73]. Citrate removal with CRRT also depends on citrate concentration in the filter and filtration fraction; high fractions are associated with relatively higher citrate clearance and a lower buffer supply to the patient.

The use of regional anticoagulation with citrate is limited by the patient's capacity to metabolize citrate, which is decreased if liver function or tissue perfusion fails [74]. Due to the citrate load associated with transfusion, patients having received a massive transfusion are also at risk of citrate accumulation. If citrate accumulates, iCa decreases and metabolic acidosis ensues, since bicarbonate continues to be removed by filtration or dialysis, while citrate is not used as a buffer. In daily clinical practice, citrate measurement is hampered by the limited stability of the reagents. However, accumulation of citrate due to decreased metabolism can be detected accurately by the symptoms of metabolic acidosis, increasing anion gap, ionized hypocalcemia, and most specifically by an increased total/iCa concentration. A ratio of more than 2.1 predicted a citrate concentration of greater

than 1 mmol/l with 89% sensitivity and 100% specificity [71]. Others use a ratio of more than 2.5 for accumulation [75].

Accumulation of citrate can also be the result of an unintended citrate over-infusion or of decreased removal in case of a decline in membrane performance at constant citrate infusion. In these cases, ionized hypocalcemia occurs together with metabolic alkalosis. Both derangements are preventable by adherence to the protocol or are detectable early by strict monitoring.

*Metabolic consequences*

Anticoagulation with citrate has complex metabolic consequences, which are related to the dual effects of citrate as an anticoagulant and a buffer. Manipulation of citrate or blood flow, ultrafiltrate, dialysate, or replacement rates, and their mutual relation changes the amount of buffer substrate entering the patient's circulation. For a constant buffer delivery, these flows are to be kept constant, while they can be adjusted to correct metabolic acidosis or alkalosis. Causes of metabolic derangements and possible adjustments are summarized in Table 2.

*Citrate solutions*

Citrate is either infused as a separate tri-sodium citrate solution or added to a calcium-free predilution replacement fluid. The strength of citrate solutions is generally expressed as a percentage (grams of tri-sodium citrate per 100 ml). Some of the solutions contain additional citric acid to reduce sodium load. Because *anticoagulatory* strength of the solution depends on the citrate concentration, it is best expressed as molar strength of citrate. Citrate solutions for postdilution CVVH(D) contain 133 to 1,000 mmol citrate per liter [73,75-82]. Citrate replacement solutions for predilution CVVH contain 11 to 15 mmol citrate per liter [83-88] and for predilution CVVHDF, 13 to 23 mmol/l [40,89-92]. The *buffer* strength of the solution is related to the conversion of tri-sodium citrate to citric acid (see formula above) and therefore to the proportion of sodium as cation.

*Modalities*

After the first report of Mehta and colleagues [76], a wide variety of homemade citrate systems for CRRT have been

**Table 2****Metabolic derangements and adjustments during citrate anticoagulation**

Derangement	Cause and signs	Adjustment
Metabolic acidosis	Insufficient removal of metabolic acids Anion gap increases	Increase continuous renal replacement therapy dose (filtrate or dialysate flow) to 35 ml/kg per hour
	Loss of buffer substrate is higher than delivery	Increase bicarbonate replacement or increase bicarbonate dialysate flow or give additional bicarbonate or increase citrate flow (cave accumulation)
	Citrate metabolism decreases (iCa decreases, totCa/iCa increases [more than 2.1-2.5], and anion gap increases)	Decrease citrate delivery or stop increase dialysate or filtrate flow increase bicarbonate replacement or increase bicarbonate dialysate flow
Metabolic alkalosis	Delivery of buffer substrate is higher than loss	Decrease bicarbonate replacement or decrease bicarbonate dialysate flow or stop additional bicarbonate i.v. or decrease citrate flow (cave anticoagulation)
	Decreased loss of buffer due to a decline in filtrate flow	Change filter Increase filtrate flow
Hypocalcemia	Loss of calcium is higher than delivery (iCa decreases and totCa/iCa is normal)	Increase i.v. calcium dose
	Citrate metabolism decreases (metabolic acidosis, totCa/iCa increases, and anion gap increases)	Increase i.v. calcium dose, decrease or stop citrate delivery increase dialysate or filtrate flow, increase bicarbonate replacement or increase bicarbonate dialysate flow
Hypercalcemia	Delivery of calcium is higher than loss	Decrease i.v. calcium dose
Hyponatremia	Delivery of sodium is higher than loss	Recalculate default settings Protocol violation <ul style="list-style-type: none"> <li>• decrease sodium replacement</li> <li>• decrease dialysate sodium content</li> <li>• decrease trisodium citrate flow</li> </ul>
	Decreased loss of sodium due to a decline in filtrate flow	Change filter
Hyponatremia	Loss of sodium is higher than delivery	Recalculate default settings Protocol violation <ul style="list-style-type: none"> <li>• increase sodium replacement</li> <li>• increase dialysate sodium content</li> <li>• increase trisodium citrate flow</li> </ul>

iCa, ionized calcium; i.v., intravenous; totCa/iCa, ratio of total to ionized calcium.

described. There are systems for CVVHD, predilutional or postdilutional CVVH, CVVHDF, and different doses of CRRT (1.5 to 4 liters per hour) (summarized in the electronic supplemental material in [9]). None of the proposed systems can attain perfect acid-base control using one standard citrate, replacement, or dialysis solution. Each protocol has its own rules to correct metabolic acidosis or alkalosis or hypocalcemia or hypercalcemia.

#### *Circuit survival and bleeding complications*

Some of the published studies compare circuit life and bleeding complications with citrate to historical or contemporary non-randomized controls on heparin (summarized in [9]) [93-95]. Because the citrate patients often had a higher

risk of bleeding, groups are generally not comparable. Nevertheless, bleeding complications were generally reduced in the citrate groups. Circuit survival with citrate was usually improved (summarized in [9]) [93], sometimes comparable [24,84,95], and in some studies shorter than with heparin [89,94]. Differences in circuit life between studies can be explained in part by the wide variety of citrate dose (2 to 6 mmol/l blood flow), fixed citrate infusion or citrate dose titrated on postfilter iCa, the use of dialysis or filtration (predilution or postdilution), differences in CRRT dose and filtration fraction, or by a reduction in citrate flow used for control of metabolic alkalosis. Only two small randomized controlled studies comparing anticoagulation with citrate to UFH have appeared in a full paper. Both show a significantly

This article is part of a review series on  
*Renal replacement therapy*,  
edited by John Kellum and Lui Forni.

Other articles in the series can be found online at  
[http://ccforum.com/articles/  
theme-series.asp?series=CC\\_Renal](http://ccforum.com/articles/theme-series.asp?series=CC_Renal)

longer circuit survival with citrate [40,82], a trend toward less bleeding [40], and less transfusion with citrate [82].

#### Safety of citrate

It may be questioned whether the benefits of citrate (less bleeding, possibly a longer circuit survival, and less bio-incompatibility [96-98]) weigh against the greater risk of metabolic derangement and possible long-term side effects like increased bone resorption [99]. Preliminary results from a large randomized controlled trial (of approximately 200 patients) comparing regional anticoagulation with citrate to nadroparin in postdilution CVVH show that citrate is safe and superior in terms of mortality to nadroparin (H.M. Oudemans-van Straaten, to be published).

#### Conclusion

Premature clotting of the CRRT circuit increases blood loss, workload, and costs. Circuit patency can be increased. Non-anticoagulation measures include optimization of vascular access (inner diameter, pattern of flow, and position), CRRT settings (partial predilution and individualized control of filtration fraction), and the training of nurses. Systemic anticoagulation interferes with plasmatic coagulation, platelet activation, or both and should be kept at a low dose to mitigate bleeding complications. Regional anticoagulation with citrate emerges as the most promising method.

#### Competing interests

The authors declare that they have no competing interests.

#### References

- Levi M, Opal SM: **Coagulation abnormalities in critically ill patients.** *Crit Care* 2006, **10**:222.
- Cardigan RA, McGloin H, Mackie IJ, Machin SJ, Singer M: **Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration.** *Kidney Int* 1999, **55**:1568-1574.
- Salmon J, Cardigan R, Mackie I, Cohen SL, Machin S, Singer M: **Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways.** *Intensive Care Med* 1997, **23**:38-43.
- Bouman CS, de Pont AC, Meijers JC, Bakhtiari K, Roem D, Zeerleder S, Wolbink G, Korevaar JC, Levi M, de Jonge E: **The effects of continuous venovenous hemofiltration on coagulation activation.** *Crit Care* 2006, **10**:R150.
- Baldwin I, Bellomo R, Koch B: **Blood flow reductions during continuous renal replacement therapy and circuit life.** *Intensive Care Med* 2004, **30**:2074-2079.
- Holt AW, Bierer P, Bersten AD, Bury LK, Vedig AE: **Continuous renal replacement therapy in critically ill patients: monitoring circuit function.** *Anaesth Intensive Care* 1996, **24**:423-429.
- de Pont AC, Oudemans-van Straaten HM, Roozendaal KJ, Zandstra DF: **Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-**

- blind, randomized, crossover study.** *Crit Care Med* 2000, **28**:421-425.
- Cutts MW, Thomas AN, Kishen R: **Transfusion requirements during continuous veno-venous haemofiltration: the importance of filter life.** *Intensive Care Med* 2000, **26**:1694-1697.
- Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR: **Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?** *Intensive Care Med* 2006, **32**:188-202.
- Unger JK, Haltern C, Portz B, Dohmen B, Gressner A, Rossaint R: **Relation of haemofilter type to venous catheter resistance is crucial for filtration performance and haemocompatibility in CVVH—an *in vitro* study.** *Nephrol Dial Transplant* 2006, **21**:2191-2201.
- Canaud B, Desmeules S, Klouche K, Leray-Moragues H, Beraud JJ: **Vascular access for dialysis in the intensive care unit.** *Best Pract Res Clin Anaesthesiol* 2004, **18**:159-174.
- Jean G, Chazot C, Vanel T, Charra B, Terrat JC, Calemard E, Laurent G: **Central venous catheters for haemodialysis: looking for optimal blood flow.** *Nephrol Dial Transplant* 1997, **12**:1689-1691.
- Mandolfo S, Borlandelli S, Ravani P, Imbasciati E: **How to improve dialysis adequacy in patients with vascular access problems.** *J Vasc Access* 2006, **7**:53-59.
- Hernández D, Díaz F, Rufino M, Lorenzo V, Pérez T, Rodríguez A, De Bonis E, Losada M, González-Posada JM, Torres A: **Subclavian vascular access stenosis in dialysis patients: natural history and risk factors.** *J Am Soc Nephrol* 1998, **9**:1507-1510.
- Agraharkar M, Isaacson S, Mendelssohn D, Muralidharan J, Mustata S, Zevallos G, Besley M, Uldall R: **Percutaneously inserted silastic jugular hemodialysis catheters seldom cause jugular vein thrombosis.** *ASAIO J* 1995, **41**:169-172.
- Oliver MJ: **Acute dialysis catheters.** *Semin Dial* 2001, **14**:432-435.
- Karakitsos D, Labropoulos N, De Groot E, Patrianakos AP, Kouraklis G, Poularas J, Samonis G, Tsoutsos DA, Konstadoulakis MM, Karabinis A: **Real-time ultrasound-guided catheterisation of the internal jugular vein: a prospective comparison with the landmark technique in critical care patients.** *Crit Care* 2006, **10**:R162.
- Weijmer MC, van den Dorpel MA, Van de Ven PJ, ter Wee PM, van Geelen JA, Groeneveld JO, van Jaarsveld BC, Koopmans MG, le Poole CY, Schrandt-Van der Meer AM, et al.: **CITRATE Study Group: Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients.** *J Am Soc Nephrol* 2005, **16**:2769-2777.
- Grudzinski L, Quinan P, Kwok S, Pierratos A: **Sodium citrate 4% locking solution for central venous dialysis catheters—an effective, more cost-efficient alternative to heparin.** *Nephrol Dial Transplant* 2007, **22**:471-476.
- Davies H, Leslie G: **Maintaining the CRRT circuit: non-anticoagulant alternatives.** *Aust Crit Care* 2006, **19**:133-138.
- Schetz M: **Anticoagulation in continuous renal replacement therapy.** *Contrib Nephrol* 2001, **132**:283-303.
- Ramesh Prasad GV, Palevsky PM, Burr R, Lesko JM, Gupta B, Greenberg A: **Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial.** *Clin Nephrol* 2000, **53**:55-60.
- Ricci Z, Ronco C, Bachetoni A, D'amico G, Rossi S, Alessandri E, Rocco M, Pietropaoli P: **Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion.** *Crit Care* 2006, **10**:R67.
- Brophy PD, Somers MJ, Baum MA, Symons JM, McAfee N, Fortenberry JD, Rogers K, Barnett J, Blowey D, Baker C, et al.: **Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT).** *Nephrol Dial Transplant* 2005, **20**:1416-1421.
- Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: **Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: impact on filter life and azotemic control.** *Nephron Clin Pract* 2003, **94**:c94-c98.
- Van der Voort PH, Gerritsen RT, Kuiper MA, Egbers PH, Kingma WP, Boerma EC: **Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation.** *Blood Purif* 2005, **23**:175-180.
- Clark WR, Gao D: **Low-molecular weight proteins in end-stage renal disease: potential toxicity and dialytic removal mecha-**



- nisms. *J Am Soc Nephrol* 2002, **13** Suppl 1:S41-S47.
28. Padrini R, Canova C, Conz P, Mancini E, Rizzioli E, Santoro A: **Convective and adsorptive removal of beta2-microglobulin during predilutional and postdilutional hemofiltration.** *Kidney Int* 2005, **68**:2331-2337.
  29. Zhu LP, Zhang XX, Xu L, Du CH, Zhu BK, Xu YY: **Improved protein-adsorption resistance of polyethersulfone membranes via surface segregation of ultrahigh molecular weight poly(styrene-alt-maleic anhydride).** *Colloids Surf B Biointerfaces* 2007, **57**:189-197.
  30. Chanard J, Lavaud S, Randoux C, Rieu P: **New insights in dialysis membrane biocompatibility: relevance of adsorption properties and heparin binding.** *Nephrol Dial Transplant* 2003, **18**:252-257.
  31. van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC: **Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage.** *J Am Soc Nephrol* 1996, **7**:145-150.
  32. Lavaud S, Canivet E, Wuillai A, Maheut H, Randoux C, Bonnet JM, Renaux JL, Chanard J: **Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.** *Nephrol Dial Transplant* 2003, **18**:2097-2104.
  33. Sperling C, Houska M, Brynda E, Streller U, Werner C: **In vitro hemocompatibility of albumin-heparin multilayer coatings on polyethersulfone prepared by the layer-by-layer technique.** *J Biomed Mater Res A* 2006, **76**:681-689.
  34. Dungen HD, von HC, Ronco C, Kox WJ, Spies CD: **Renal replacement therapy: physical properties of hollow fibers influence efficiency.** *Int J Artif Organs* 2001, **24**:357-366.
  35. Bellomo R, Teede H, Boyce N: **Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study.** *Intensive Care Med* 1993, **19**:329-332.
  36. Tan HK, Baldwin I, Bellomo R: **Continuous veno-venous hemofiltration without anticoagulation in high-risk patients.** *Intensive Care Med* 2000, **26**:1652-1657.
  37. Fiore G, Donadio PP, Gianferrari P, Santacroce C, Guermani A: **CVVH in postoperative care of liver transplantation.** *Minerva Anestesiol* 1998, **64**:83-87.
  38. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: **Continuous venovenous hemofiltration without anticoagulation.** *ASAIO J* 2004, **50**:76-80.
  39. Bastien O, French P, Paulus S, Filley S, Berruyer M, Dechavanne M, Estanove S: **Antithrombin III deficiency during continuous venovenous hemodialysis.** *Contrib Nephrol* 1995, **116**:154-158.
  40. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J: **Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients.** *Kidney Int* 2005, **67**:2361-2367.
  41. Joannes-Boyau O, Laffargue M, Honore P, Gauche B, Fleureau C, Roze H, Janvier G: **Short filter life span during hemofiltration in sepsis: antithrombin (AT) supplementation should be a good way to sort out this problem.** *Blood Purif* 2005, **23**:149-174.
  42. du Cheyron D, Bouchet B, Bruel C, Daubin C, Ramakers M, Charbonneau P: **Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study.** *Crit Care* 2006, **10**:R45.
  43. Esmon CT: **The protein C pathway.** *Chest* 2003, **124**:26S-32S.
  44. de Pont AC, Bouman CS, de Jonge E, Vroom MB, Büller HR, Levi M: **Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis.** *Intensive Care Med* 2003, **29**:1205.
  45. Ricci Z, Ronco C, D'amico G, De Felice R, Rossi S, Bolgan I, Bonello M, Zamperetti N, Petras D, Salvatori G, et al.: **Practice patterns in the management of acute renal failure in the critically ill patient: an international survey.** *Nephrol Dial Transplant* 2006, **21**:690-696.
  46. De Waele JJ, Van Cauwenberghe S, Hoste E, Benoit D, Colardyn F: **The use of the activated clotting time for monitoring heparin therapy in critically ill patients.** *Intensive Care Med* 2003, **29**:325-328.
  47. Hirsh J, Raschke R: **Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.** *Chest* 2004, **126**:188S-203S.
  48. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: **Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.** *N Engl J Med* 1995, **332**:1330-1335.
  49. Elisaf MS, Germanos NP, Bairaktari HT, Pappas MB, Koulouridis EI, Siamopoulos KC: **Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients.** *Am J Nephrol* 1997, **17**:153-157.
  50. Leitienne P, Fouque D, Rigal D, Adeleine P, Trzeciak MC, Laville M: **Heparins and blood polymorphonuclear stimulation in haemodialysis: an expansion of the biocompatibility concept.** *Nephrol Dial Transplant* 2000, **15**:1631-1637.
  51. Jeffrey RF, Khan AA, Douglas JT, Will EJ, Davison AM: **Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit.** *Artif Organs* 1993, **17**:717-720.
  52. Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD: **A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration.** *Crit Care Med* 1999, **27**:2224-2228.
  53. Joannidis M, Kountchev J, Rauchenzauner M, Schusterschitz N, Ulmer H, Mayr A, Bellmann R: **Enoxaparin versus unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration - a randomized controlled cross-over study.** *Intensive Care Med* 2007 Jun 12; [Epub ahead of print].
  54. Isla A, Gascón AR, Maynar J, Arzuaga A, Corral E, Martín A, Solinis MA, Muñoz JL: **In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.** *Clin Ther* 2005, **27**:1444-1451.
  55. Greaves M: **Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.** *Thromb Haemost* 2002, **87**:163-164.
  56. Warkentin TE, Greinacher A: **Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.** *Chest* 2004, **126**:311S-337S.
  57. Wester JP, Oudemans-van Straaten HM: **How do I diagnose HIT?** *Neth J Crit Care* 2006, **10**:61-65.
  58. Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG: **Frequency of heparin-induced thrombocytopenia in critical care patients.** *Pharmacotherapy* 2003, **23**:745-753.
  59. Wester JP, Leyte A, Oudemans-van Straaten HM, Bosman RJ, van der Spoel JJ, Haak EA, Porcelijn L, Zandstra DF: **Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.** *Neth J Med* 2007, **65**:101-108.
  60. Vargas Hein O, von Heymann C, Lipps M, Ziemer S, Ronco C, Neumayer HH, Morgera S, Welte M, Kox WJ, Spies C: **Hirudin versus heparin for anticoagulation in continuous renal replacement therapy.** *Intensive Care Med* 2001, **27**:673-679.
  61. Magnani HN: **Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with organan (Org 10172).** *Thromb Haemost* 1993, **70**:554-561.
  62. Dager WE, White RH: **Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.** *Ann Pharmacother* 2003, **37**:1232-1236.
  63. Williamson DR, Boulanger I, Tardif M, Albert M, Gregoire G: **Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction.** *Pharmacotherapy* 2004, **24**:409-414.
  64. Tang IY, Cox DS, Patel K, Reddy BV, Nahlik L, Trevino S, Murray PT: **Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia.** *Ann Pharmacother* 2005, **39**:231-236.
  65. Murray PT, Reddy BV, Grossman EJ, Hammes MS, Trevino S, Ferrell J, Tang I, Hursting MJ, Shamp TR, Swan SK: **A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease.** *Kidney Int* 2004, **66**:2446-2453.
  66. Fiaccadori E, Maggiore U, Rotelli C, Minari M, Melfa L, Cappè G, Cabassi A: **Continuous haemofiltration in acute renal failure with prostacyclin as the sole anti-haemostatic agent.** *Intensive Care Med* 2002, **28**:586-593.

67. Davenport A, Will EJ, Davison AM: **Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure.** *Nephron* 1994, **66**:431-437.
68. Kozek-Langenecker SA, Kettner SC, Oismueller C, Gonano C, Speiser W, Zimpfer M: **Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltration.** *Crit Care Med* 1998, **26**:1208-1212.
69. Kozek-Langenecker SA, Spiss CK, Gamsjager T, Domenig C, Zimpfer M: **Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial.** *Wien Klin Wochenschr* 2002, **114**:96-101.
70. Kozek-Langenecker SA, Spiss CK, Michalek-Sauberer A, Felfernig M, Zimpfer M: **Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.** *Crit Care Med* 2003, **31**:864-868.
71. Bakker AJ, Boerma EC, Keidel H, Kingma P, van der Voort PH: **Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium.** *Clin Chem Lab Med* 2006, **44**:962-966.
72. Chadha V, Garg U, Warady BA, Alon US: **Citrate clearance in children receiving continuous venovenous renal replacement therapy.** *Pediatr Nephrol* 2002, **17**:819-824.
73. Swartz R, Pasko D, O'Toole J, Starmann B: **Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation.** *Clin Nephrol* 2004, **61**:134-143.
74. Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, Gangl A: **Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients.** *Crit Care Med* 2003, **31**:2450-2455.
75. Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T: **Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation.** *Crit Care Med* 2001, **29**:748-752.
76. Mehta RL, McDonald BR, Aguilar MM, Ward DM: **Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients.** *Kidney Int* 1990, **38**:976-981.
77. Ward DM, Mehta RL: **Extracorporeal management of acute renal failure patients at high risk of bleeding.** *Kidney Int Suppl* 1993, **41**:S237-S244.
78. Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG: **Simplified citrate anticoagulation for continuous renal replacement therapy.** *Kidney Int* 2001, **60**:370-374.
79. Tobe SW, Aujla P, Walele AA, Oliver MJ, Naimark DM, Perkins NJ, Beardsall M: **A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions.** *J Crit Care* 2003, **18**:121-129.
80. Mitchell A, Daul AE, Beiderlinden M, Schafers RF, Heemann U, Kribben A, Peters J, Philipp T, Wenzel RR: **A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD).** *Clin Nephrol* 2003, **59**:106-114.
81. Morgera S, Scholle C, Voss G, Haase M, Vargas-Hein O, Krausch D, Melzer C, Rosseau S, Zuckermann-Becker H, Neumayer HH: **Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience.** *Nephron Clin Pract* 2004, **97**:c131-c136.
82. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: **Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study.** *Intensive Care Med* 2004, **30**:260-265.
83. Palsson R, Niles JL: **Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding.** *Kidney Int* 1999, **55**:1991-1997.
84. Thoenen M, Schmid ER, Binswanger U, Schuepbach R, Aerne D, Schmidlin D: **Regional citrate anticoagulation using a citrate-based substitution solution for continuous venovenous hemofiltration in cardiac surgery patients.** *Wien Klin Wochenschr* 2002, **114**:108-114.
85. Hofmann RM, Maloney C, Ward DM, Becker BN: **A novel method for regional citrate anticoagulation in continuous venovenous hemofiltration (CVVHF).** *Ren Fail* 2002, **24**:325-335.
86. Egi M, Naka T, Bellomo R, Cole L, French C, Trethewey C, Wan L, Langenberg CC, Fealy N, Baldwin I: **A comparison of two citrate anticoagulation regimens for continuous venovenous hemofiltration.** *Int J Artif Organs* 2005, **28**:1211-1218.
87. Naka T, Egi M, Bellomo R, Cole L, French C, Botha J, Wan L, Fealy N, Baldwin I: **Commercial low-citrate anticoagulation haemofiltration in high risk patients with frequent filter clotting.** *Anaesth Intensive Care* 2005, **33**:601-608.
88. Bihorac A, Ross EA: **Continuous venovenous hemofiltration with citrate-based replacement fluid: efficacy, safety, and impact on nutrition.** *Am J Kidney Dis* 2005, **46**:908-918.
89. Gabutti L, Marone C, Colucci G, Duchini F, Schonholzer C: **Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge.** *Intensive Care Med* 2002, **28**:1419-1425.
90. Dorval M, Madore F, Courteau S, Leblanc M: **A novel citrate anticoagulation regimen for continuous venovenous hemodiafiltration.** *Intensive Care Med* 2003, **29**:1186-1189.
91. Cointault O, Kamar N, Bories P, Lavayssiere L, Angles O, Rostaing L, Genestal M, Durand D: **Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions.** *Nephrol Dial Transplant* 2004, **19**:171-178.
92. Gupta M, Wadhwa NK, Bukovsky R: **Regional citrate anticoagulation for continuous venovenous hemodiafiltration using calcium-containing dialysate.** *Am J Kidney Dis* 2004, **43**:67-73.
93. Bagshaw SM, Laupland KB, Boiteau PJ, Godinez-Luna T: **Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system.** *J Crit Care* 2005, **20**:155-161.
94. Van der Voort PH, Postma SR, Kingma WP, Boerma EC, Van Roon EN: **Safety of citrate based hemofiltration in critically ill patients at high risk for bleeding: a comparison with nadroparin.** *Int J Artif Organs* 2006, **29**:559-563.
95. Spronk PE, Steenbergen H, ten Kleij M, Rommes JH: **Re: Regional citrate anticoagulation does not prolong filter survival during CVVH.** *J Crit Care* 2006, **21**:291-292.
96. Gabutti L, Ferrari N, Mombelli G, Keller F, Marone C: **The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation.** *J Nephrol* 2004, **17**:819-825.
97. Bos JC, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nubé MJ: **Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis.** *Nephrol Dial Transplant* 1997, **12**:1387-1393.
98. Gritters M, Grooteman MP, Schoorl M, Schoorl M, Bartels PC, Scheffer PG, Teerlink T, Schalkwijk CG, Spreeuwenberg M, Nubé MJ: **Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis.** *Nephrol Dial Transplant* 2006, **21**:153-159.
99. Wang PL, Meyer MM, Orloff SL, Anderson S: **Bone resorption and "relative" immobilization hypercalcemia with prolonged continuous renal replacement therapy and citrate anticoagulation.** *Am J Kidney Dis* 2004, **44**:1110-1114.